Axsome Therapeutics (AXSM) to Release Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) is scheduled to post its quarterly earnings results before the market opens on Monday, May 6th. Analysts expect the company to announce earnings of ($1.22) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, February 20th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($1.21) by $0.48. Axsome Therapeutics had a negative return on equity of 70.67% and a negative net margin of 88.41%. The firm had revenue of $71.53 million during the quarter, compared to analysts’ expectations of $70.38 million. On average, analysts expect Axsome Therapeutics to post $-4 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $74.80 on Friday. The business has a 50-day simple moving average of $74.41 and a two-hundred day simple moving average of $75.42. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.52 and a current ratio of 3.63. The firm has a market cap of $3.55 billion, a price-to-earnings ratio of -14.38 and a beta of 1.13. Axsome Therapeutics has a fifty-two week low of $55.02 and a fifty-two week high of $98.40.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 24,662 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total value of $1,904,892.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Mark L. Jacobson sold 24,662 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total value of $1,904,892.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roger Jeffs sold 29,976 shares of Axsome Therapeutics stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the transaction, the director now directly owns 120,756 shares in the company, valued at $8,416,693.20. The disclosure for this sale can be found here. 24.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Royal Bank of Canada boosted their target price on shares of Axsome Therapeutics from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, April 10th. Piper Sandler increased their target price on Axsome Therapeutics from $90.00 to $113.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 16th. Mizuho increased their price objective on shares of Axsome Therapeutics from $108.00 to $109.00 and gave the company a “buy” rating in a report on Thursday, March 28th. Finally, Guggenheim boosted their target price on shares of Axsome Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, February 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $122.00.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.